興科蓉醫藥：環境、社會及管治報告2023.pdf

1、2023 ENVIRONMENTAL,SOCIAL AND GOVERNANCE REPORT 環境、社會及管治報告Environmental,Social andGovernance Report環境、社會及管治報告2Sinco Pharmaceuticals Holdings Limited Environmental,Social and Governance Report 2023Environmental,Social and Governance Report環境、社會及管治報告Board of Directors StatementThe ESG StructureThe Boa

2、rd of Directors(“the Board”)of Sinco Pharmaceuticals Holdings Limited and all its subsidiaries(collectively referred to as“the Group”or“we”)recognises the importance of Environmental,Social and Governance(“ESG”)in meeting the changing expectations of stakeholders while enhancing the value and perfor

3、mance of the Group.Hence the Board,in collaboration with the management,has made the commitment to take full responsibility of assessing and identifying risks associated with ESG,and promote environmentally and socially sustainable culture among employees,thereby maintaining the sustainable growth o

4、f the Group.In order to elevate the ESG matters to a more important position in corporate governance,the Group plans to set up the ESG committee under the Board in the future.The ESG committee is tasked with the important roles in providing supervision and guidance,ensuring that ESG matters are inco

5、rporated into the business decision making process.ESG Management Approach and StrategyThe Group attaches importance to the suggestions and opinions of stakeholders and ensures sufficient channels for the communication with key stakeholders to discuss and identify the Groups important ESG issues and

6、 ESG risks it may face,continuously improving ESG-related strategies as well as policies and systems.We collected and compiled focus topics of stakeholders and continued to respond to key issues and suggestions from stakeholders after conducting extensive and in-depth communication with them through